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Abstract
Glioblastoma (also called glioblastoma multiforme – GBM) is a primary brain neoplasm, 
representing about 55% of all gliomas. It is a very aggressive and infiltrative tumor. 
Glioblastoma is usually highly malignant, with more than 90% 5-year mortality and 
a median survival of about 14.6 months. Compared to other cancers, the survival rate 
has not greatly changed over time and no current treatment is curative for this disease. 
Because the tumor has a heterogeneous cell population containing several types of cells, 
the treatment for GBM is one of the most challenging in clinical oncology. This chapter 
will discuss the current approaches in glioblastoma treatment, including resection tech-
niques, chemotherapy and radiation therapy.
Keywords: glioblastoma, surgical resection, intraoperative guidance, radiation therapy, 
chemotherapy, intratumoral therapies, targeted therapy
1. Introduction
Glioblastoma is the most common primary brain malignancy in adults. It is the most aggres-
sive of the gliomas, largely resistant to conventional therapies, having a very poor prognosis. 
The global incidence is 2–3 newly diagnosed cases per 100,000 people per year in the United 
States and Europe. According to Central Brain Tumor Registry of the United States, GBM 
accounts for 14.9% of all primary brain tumors and 55.4% of all gliomas. It represents the high-
est number of cases of all malignant tumors, with an estimated 12,390 new cases predicted 
in 2017. Currently, the standard of care (SoC) for patients with GBM consists of maximal 
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safe surgical resection, followed by concurrent chemoradiotherapy and adjuvant chemother-
apy with temozolomide (TMZ). New discoveries are being made in basic and translational 
research, novel therapeutic approaches have been tried and tested, some of them finding their 
way into clinical practice. Despite the synergistic multimodal strategies and individualized 
therapies, the available treatment is of limited utility, and patients have a poor prognosis, 
with a progression-free survival (PFS) of 7–8 months, a median survival of 14–16 months and 
5-year overall survival (OS) of 9.8% [1]. This review focuses on the current treatment strate-
gies and perspectives in the management of GBM.
2. Histology and classification
The cellular origin of GBM is unknown. Astrocyte, oligodendrocyte precursor cell and neu-
ral stem cell can all serve as the cell of origin for this type of brain tumor. For this reason, in 
the recent version of the 2016 World Health Organization (WHO) Classification of Tumors 
of the Central Nervous System (CNS), which is the current international standard for the 
nomenclature and diagnosis, GBM is incorporated into the category of “diffuse astrocytic and 
oligodendroglial tumors”, being considered a grade IV tumor.
There are some properties of the tumor cells that render GBM incurable. First, the dif-
fuse infiltrative nature of the cells makes complete tumor resection impossible, despite the 
advances in neurosurgical techniques. Glioma cells have the ability to migrate away from 
the main tumor mass, through the brain. Typical migration routes include white matter 
tracts, along the basal lamina of the blood vessels, perineuronal and in between the glia 
limitans and the pia mater. Tumor cells are still detectable at a distance greater than 4 cm 
away from macroscopic and radiologic margin of the tumor [2]. Second, there is a resistance 
of the glioma cells to conventional radiation therapy, chemotherapy and other therapies, 
as they are spared from eradication. This resistance is correlated with the heterogeneous 
character of the tumor itself, with its “multiforme” appearance [3]. GBM is multiforme mac-
roscopically, featuring multifocal hemorrhage, necrosis and cystic areas. It is multiforme 
microscopically, demonstrating pleomorphic cell population, hypercellularity with mitotic 
activity, nuclear atypia, pseudopalisading necrosis and microvascular proliferation. And it 
is multiforme genetically, with various genetic abnormalities and heterogeneous subclones 
within the tumor cell population.
The histological diagnosis of GBM should be undertaken by a neuropathologist by standard 
histopathology methods and should include tumor type and tumor grade according to WHO 
Classification of Tumors of the CNS.
Progress has been made in knowledge of the GBM biology in relation to its microenviron-
ment. Patterns of molecular genetic alterations have been associated with specific types 
of GBMs. Recent medical advances have indicated the importance of molecular typing in 
determining the prognosis and personalized treatment strategies for the patient. For this 
reason, in the recent version of the 2016 WHO Classification of Tumors of the CNS, molecu-
lar parameters are used in addition to histology to define diagnostic entities. This adds 
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a level of objectivity to diagnostic and should lead to improvements in determination of 
prognosis and treatment response. So, GBMs are further defined by the presence or absence 
of isocitrate dehydrogenase (IDH) gene mutations. IDH is an enzyme encoded by the IDH 
gene, whose mutations occur in gliomas. These mutations are oncogenic and they lead to 
a hypermethylation phenotype, as well as changes in cellular metabolism and response to 
hypoxic and oxidative stress [4, 5]. Mutated IDH can now be detected by immunohisto-
chemistry and magnetic resonance spectroscopy (MRS). IDH mutation is identified as a 
genetic marker of secondary GBM. It can indicate a favorable prognosis and a relatively 
good response to radiation and/or alkylating chemotherapy.
GBMs are divided into: GBM, IDH-wildtype; GBM, IDH-mutant and GBM, NOS [6]. IDH-
wildtype GBM corresponds with clinically described primary or de novo GBM. It represents 
about 90% of GBMs. It arises without clinical, radiologic or histologic evidence of a pre-exist-
ing less malignant lesions, in elderly patients (median age of 62 years), usually supratentorial. 
The mean length of clinical history is 4 months and the median overall survival after con-
ventional surgery, radiotherapy and chemotherapy is 15 months, the prognosis being poor 
[6, 7]. IDH-mutant GBM corresponds with secondary GBM (approximately 10% of GBMs). 
It typically develops from lower grade diffuse glioma. It occurs in younger patients (median 
age of 45 years), preferentially in the frontal lobe. The mean duration of the clinical history 
of secondary GBM is 15 months and the median overall survival after multimodal treatment 
(including surgical resection, radiotherapy and chemotherapy) is 31 months, a significantly 
better prognosis than primary GBM [6, 7]. Primary and secondary GBMs carry distinct genetic 
abnormalities. Other common genetic alterations in secondary GBMs include TP53 muta-
tions (~65%), ATRX mutations (~65%) and loss of heterozygosity (LOH) on chromosome 19q 
(~50%). In primary GBMs, there is a high frequency of EGFR amplification (~35%), phospha-
tase and tensin homolog (PTEN) mutation (~25%) and LOH on chromosome 10 (LOH 10p 
~50%, LOH 10q ~70%) [7, 8]. There is now increasing evidence that primary and secondary 
GBMs are in fact different tumor entities that develop from distinct cells of origin [7]. Despite 
the differences in their phenotypic and genotypic profiles, these two subtypes of GBM are his-
topathologically indistinguishable, except that extensive necrosis is more frequent in primary 
GBM and oligodendroglioma components are more frequent in secondary GBM [7]. Recent 
findings in pediatric GBMs regarding mutations in the histone H3F3A gene suggest that these 
tumors may represent a third major category of GBMs, separate from adult primary and sec-
ondary GBMs [9]. The terminology NOS (i.e., not otherwise specified) is used for GBM when 
molecular information is insufficient, either because testing cannot be fully performed or the 
results do not fit within a defined category.
In the 2016 update of the WHO Classification of Tumors of the CNS, there are three variants 
of IDH-wildtype GBMs: giant cell GBM, gliosarcoma and epithelioid GBM. It is to be noted 
that variants are subtypes of accepted entities that are sufficiently well characterized patho-
logically and have potential clinical utility [6]. There are also different patterns in GBMs, 
including small cell GBMs, granular cell GBM and GBM with primitive neuronal component 
(previously referred as GBM with primitive neuroectodermal tumor (PNET)-like compo-
nent). Patterns are histological features that are readily recognizable, but usually do not have 
clear clinicopathological significance [6].




GBMs are typically large tumors at diagnosis. They occur most commonly in the supratento-
rial compartment and are less common in the posterior fossa and brainstem. Lesions usually 
start within the deep white matter, but often infiltrate into cortex (Figure 1), deep nuclei or 
through commissural pathways into the contralateral hemisphere.
When a GBM spreads across the corpus callosum, there is a characteristic appearance of 
bihemispheric involvement, resulting in the classic “butterfly” pattern on imaging (Figure 2).
The vast majority of GBMs are solitary lesions, but cases of multiple GBMs were observed in 
0.5–1% of cases. Multiple gliomas can be categorized as multifocal or multicentric. Multifocal 
disease consists of multiple tumors which result from dissemination along an established 
route of CNS, spreading through white matter tracts, cerebrospinal fluid pathways or through 
local extension by satellite formations. They can be separated by abnormal white matter tracts 
within the same hemisphere (demonstrated by contiguous areas of modified T2-weighted 
signal on cerebral MRI (Figure 3).
On the other hand, multicentric disease represents multiple tumors with normal intervening 
brain, so widely separated masses in different lobes or hemispheres (Figure 4).
Although GBM is an invasive tumor, dissemination remains limited to the central nervous sys-
tem and extracranial metastases are very rare (0.4–2%). GBMs usually appear like a mass with 
thick, irregular margins and a central necrotic core, sometimes with a hemorrhagic compo-
nent. Tumors are surrounded by a vasogenic edema, characterized by extensive infiltration of 
tumor cells. This edema causes additional mass effect and leads to neurological disturbances.
The diagnosis of brain tumors must be evoked in any adult with symptoms of raised intracra-
nial pressure, seizures or focal neurological deficit, the onset being usually weeks to months 
before. The clinical presentation is nonspecific and can vary widely, depending on the tumor 
localization and the rate of growth. Rarely, an intratumoral hemorrhage occurs and patient 
may present with sudden stroke-like symptoms. GBMs may occur at any age, but 70% of 
cases are seen between 45 and 70 years of age, with a mean age at the time of diagnosis being 
53 years [10]. Men are more frequently involved (there is a sex ratio of 3:2).
Figure 1. Corticalized glioblastoma – Macroscopic appearance.
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All patients, who are presented with symptoms that could be caused by an intracranial mass, 
require neuroimaging to establish the cause of these symptoms. CT scan is often the first 
examination, because it is widely available, fast and inexpensive. Typical findings for GBM 
on CT scan are a heterogeneous mass lesion, with an isodense to slightly hyperdense irregular 
thick ring and a hypodense core representing necrosis. There is an intense, irregular and het-
erogeneous contrast enhancement of the tumor mass (Figure 5). Images highlight a significant 
surrounding cerebral edema and a marked mass effect. CT scan is helpful in demonstrating 
the presence of intratumoral hemorrhage or calcification, which is thought to be related to a 
pre-existing oligodendroglial lesion.
While CT scan provides initial data, contrast-enhanced MRI is the imaging modality of choice 
for GBMs, because of his greater accuracy and multi-planar imaging capabilities. All patients 
with a suspected brain tumor should have an MRI evaluation, unless it would be unsafe for 
them. It will confirm the diagnosis, will refine the diagnosis and will provide additional data 
needed for treatment planning. On T1-weighted images, GBMs typically appear as a hypo to 
isointense mass with central heterogeneous signal (necrosis, intratumoral hemorrhage and 
cysts), thick, irregular or poorly defined margins and peritumoral edema. After the admin-
istration of contrast medium, a heterogeneous or irregular ring-like enhancement is almost 
always present. T2-weighted and fluid-attenuated inversion recovery (FLAIR) images reveal 
a heterogeneous, hyperintense mass with adjacent tumor infiltration/vasogenic edema. 
Figure 2. Butterfly glioblastoma – MRI features. Tumor involves both cerebral hemispheres by crossing the corpus 
callosum – Bifrontal localization. (a) Sagittal T1-weighted image with contrast; (b) axial T1-weighted image with contrast; 
(c) coronal T1-weighted image with contrast; (d) axial T2-weighted image; (e) sagittal fluid-attenuated inversion recovery 
(FLAIR) sequence; (f) axial diffusion-weighted image (DWI).
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Surrounding infiltrative edema (which is a combination of increased interstitial water and 
neoplastic cells) is better appreciated in T2-weighted images as compared with T1-weighted 
images (Figures 5 and 6).
Advanced imaging technologies have been developed, including diffusion-weighted imaging 
(DWI), diffusion tensor imaging (DTI), perfusion-weighted imaging (PWI) and MR spectros-
copy (MRS). Diffusion-weighted imaging (DWI) allows the calculation of the apparent diffu-
sion coefficient (ADC) that is correlated with tumor cellularity and tumor grade. Diffusion 
tensor imaging (DTI) offers the possibility to identify and to characterize the white matter 
tracts. Perfusion-weighted imaging (PWI) provides useful information about the cerebral 
microcirculation and allows the development of cerebral blood volume maps. MR spectros-
copy (MRS) allows in vivo measurements of certain tissue metabolites. These techniques 
focus on pathophysiological changes in disease and offer potential indications on differential 
diagnosis and individual anatomy. Post-therapeutic MRI examinations are used to monitor 
treatment response and to differentiate radionecrosis from residual or recurrent tumor.
Figure 3. Multifocal glioblastoma – MRI features. There are two separate tumor foci in the right frontal lobe: A smaller 
one in the basal frontal region and a bigger one in the anterior frontal region. The presence of connecting signal alteration 
in T2-weighted images defines multifocal lesions. (a) Coronal T1-weighted image with contrast, with section line at the 
level of smaller tumor; (b) axial T1-weighted image with contrast – Section level is indicated in (a); (c) axial T2-weighted 
image – Section level is indicated in (a); (d) coronal T1-weighted image with contrast, with section line at the level of 
bigger tumor; (e) axial T1-weighted image with contrast – Section level is indicated in (d); (f) axial T2-weighted image 
– Section level is indicated in (d).
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Figure 4. Multicentric synchronous glioblastoma – MRI features. There are widely separated lesions, occurring 
in different lobes or hemispheres, with no connection between foci. They were already present at the time of initial 
radiological investigation. The figures (a), (b), (c) and (d) demonstrate a left paraventricular occipital tumor: (a) axial 
T2-weighted image; (b) axial FLAIR sequence; (c) axial T1-weighted image with contrast; (d) sagittal T1-weighted image 
with contrast. The figures (e) and (f) illustrate a left posterior temporal lesion: (e) axial T2-weighted image; (f) axial 
FLAIR sequence. The figures (g) and (h) present a right deep temporal lesion: (g) axial T2-weighted image; (h) axial 
FLAIR sequence.The figures (i) and (j) reveals a left temporomesial lesion: (i) axial T2-weighted image; (j) axial FLAIR 
sequence.
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Positron emission tomography (PET) can be used to provide additional metabolic informa-
tion of the tumor. This technique is based on the detection of radioactivity emitted by bio-
chemically active molecules labeled with radiotracers. Different molecular processes can be 
investigated including glucose consumption, expression of amino acid transporters, prolif-
eration rate, membrane biosynthesis and hypoxia. The glucose analog 18F-fluorodeoxyglucose 
(18F FDG) is the most commonly used radiotracer for PET to measure the local metabolic 
rate of glucose. Increased glucose metabolism is a feature of high-grade glioma (HGG) and a 
positive correlation between glycolysis rate and malignancy was demonstrated. Radiolabeled 
amino acids (like 11C Methionine—11C MET) have been introduced as suitable tracers in brain 
tumors, because amino acid transport as well as protein synthesis were both demonstrated to 
be enhanced in HGG. Even more, 11C MET has increased specificity and sensitivity, highlight-
ing areas of cellular proliferation correlating well with the Ki-67 labeling index of prolifera-
tion and with microvascular density. PET can help distinguish GBMs from other brain lesions 
pre-operatively, can reveal malignant transformation in low-grade gliomas (LGG), and can 
evaluate the tumor extension for an appropriate site for biopsy, for surgery planning or for 
radiation therapy planning. PET is also important in assessment of treatment response, being 
beneficial for differentiation of tumor tissue from post-therapeutic changes.
In patients with a suspected diagnosis of GBMs, initial management is intended to con-
trol symptoms and prepare the patients for surgery. Corticosteroid therapy reduces peri-
tumoral edema and alleviates symptoms of raised intracranial pressure and neurologic 
Figure 5. Left temporal glioblastoma. (a) CT scan without contrast; (b) CT scan with contrast; (c) MRI – Axial T2-weighted 
image; (d) MRI – Coronal FLAIR sequence; (e) MRI – Axial T1-weighted image with contrast; (f) MRI – Coronal 
T1-weighted image with contrast.
Brain Tumors - An Update10
symptoms, making surgery safer. Anticonvulsants are necessary when a history of seizures 
exists. However, prophylactic use of antiepileptic drugs outside the perioperative phase is 
controversial.
Ideally, all patients with GBMs should be managed by a multidisciplinary team in a central-
ized neurosciences center. The neuro-oncology group should include specialists from neuro-
radiology, neurology, neurosurgery, neuropathology, intensive care, medical and radiation 
oncology, neurorehabilitation, etc.
4. Surgical management
Neuroimaging modalities provide a lot of data about mass lesion, but cannot reliably predict the 
diagnosis of tumor type and grade. Histological assessment is required. Thus, a representative 
tissue sample should be obtained by biopsy or resection to have a correct diagnosis before spe-
cific adjunctive therapies have been initiated. The neurosurgeon is involved in decision-making 
regarding the appropriate surgical procedure for patients with GBM. Based on preoperative 
evaluation, he must indicate either an open surgical resection for both diagnosis and treatment 
or only a biopsy for diagnosis. Special consideration should be given to some important fac-
tors, including age of the patient, location and size of the tumor, neurological status, functional 
impairment (quantified by Karnofsky Performance Status (KPS) Scale), significant comorbidity 
Figure 6. Right temporal glioblastoma – MRI features. (a) Axial T1-weighted image; (b) axial T2-weighted image; (c) 
coronal FLAIR sequence; (d) axial T1-weighted image with contrast; (e) coronal T1-weighted image with contrast; (f) 
sagittal T1-weighted image with contrast.
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and patient and family preferences. Patients with GBM should have surgery for maximal tumor 
removal whenever safe, because this could prolong their survival when compared with biopsy, 
subtotal or partial resection. Biopsy is only indicated in cases of “inoperability” of the tumor, 
because of the associated risks are minimal. The image-guided stereotactic techniques are pre-
ferred over open biopsy.
4.1. Stereotactic biopsy
Stereotactic biopsy enables safe retrieval of sufficient material to allow pathologic diagnosis from 
precise targets in GBMs with the help of MRI or CT scan. Framed or frameless stereotactic biopsy 
can be performed. The main indications are inaccessible tumor location (deep-seated lesion), 
multiple or bilateral disease, potential unacceptable surgical morbidity because of eloquent 
adjacent brain areas, poor performance status (KPS < 60), lesion in a surgically poor candidate 
because of significant medical problems. When the diagnosis of GBM versus other space-occu-
pying lesions is in doubt, biopsy may be a better initial step. Stereotactic biopsy is a minimally 
invasive technique, with low risk and good diagnostic accuracy, which can provide valuable 
information, guiding further treatment. However, an average morbidity rate of 4.1% (range, 0.7–
7%) and a mortality rate of 0.9% (range, 0.2–2.3%) have been demonstrated [11]. Owing to histo-
logical heterogeneity, it leads to an inaccurate or imprecise diagnosis in about 10% of cases. There 
are approximately 15–20% of patients who undergo only biopsy as a surgical procedure [12].
4.2. Open surgical resection
To date, surgery for resection remains the first and the most important treatment modality in 
GBMs. The goal of surgery should be to remove as much of the tumor as possible, while mini-
mizing damage to surrounding healthy brain. Unfortunately, surgery is not curative. Because 
of the highly aggressive and invasive nature of the GBM, a complete resection is not possible. 
Despite the relative lack of appropriately designed trials, experience strongly supports the 
fact that gross-total resection (GTR) of the entire area of gadolinium-enhancement tumor is 
associated with improved outcome. Therefore, the current trend is to perform maximal tumor 
removal whenever possible, while minimizing the risk for unacceptable neurological deficit, 
aimed to both improve the quality of life and prolong survival.
There are some reasons for surgery on lesions thought to be GBMs. The first indication is to 
obtain a histological diagnosis. Owing to glioma histological heterogeneity, multiple biologi-
cal samples from separate places of the tumor should be taken and examined. Open resection 
can provide a larger tissue specimen as compared to biopsy. Provision of tumor for research 
and scientific analysis also could be beneficial for the patient. The second indication is to 
perform a surgical decompression that can relieve intracranial hypertension, can improve 
neurologic functions and can prevent death due to brain herniation. The third indication is 
to reduce the tumor mass as much as possible. Reduction of the tumor burden provides a 
rapid drop in the global tumoral cell population, removes resistant cells and prolongs sur-
vival. Extensive resection of the tumor may potentiate or facilitate radiation therapy, chemo-
therapy, immunotherapy or other modalities of treatment. The fourth indication is to deliver 
adjuvant therapies, including intratumoral chemotherapy, intracavitary brachytherapy, gene 
therapy, immunotherapy, photodynamic therapy, etc. Radical surgery to the extent feasible 
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should be recommended whenever is possible, regardless of age. Relative contraindications 
include inaccessible or eloquent location, poor performance status and important comorbidi-
ties. Typically, tumors located in the basal ganglia, thalamus, corpus callosum, brain stem or 
multiple tumors are biopsied only.
Proper patient selection and preoperative planning are very important for the success of 
the surgical intervention. The decision to undergo radical surgery needs to be reasonable 
and the surgical approach must be individualized for each patient. Careful assessment of the 
preoperative MRI imaging studies is essential for preoperative planning. The tumor location 
determines the type of approach to be used and the optimal trajectory to the lesion. The neu-
rosurgeon should measure the tumor dimensions in all three axes on the contrast-enhanced 
MRI and compare them with on-site measurements for a good estimation of the extent of 
resection (EOR). If there is concern regarding proximity of the tumor to eloquent areas, a 
functional MRI can help to highlight the location of critical brain regions. Consequently, the 
surgeon can plan the operative technique and can take the decision to perform intraoperative 
mapping (sometimes an awake craniotomy is needed). The blood oxygenation level-depen-
dent functional MRI (BOLDfMRI) is used in the clinical practice for presurgical mapping of 
motor areas and language areas (lateralization and localization). It works by recording subtle 
changes in blood oxygenation and flow that occur in response to a particular neural activity. 
It produces activation maps.
Maximal safe tumor resection represents the mainstay in GBM treatment. Tumor removal 
involves standard neurosurgical techniques. A good knowledge of surgical anatomy and 
a meticulous microsurgical technique, while preserving brain functions are essential. To 
increase the precision and the safety of the surgery, the specialist can use various technolo-
gies which allow intraoperative guidance. Neurosurgery for patients with GBM should be 
conducted in accredited facilities, that have the appropriate neurosurgical equipment and 
trained staff and where there is a specific multidisciplinary team.
Ideally, the extent of resection (EOR) should be assessed after surgery. This must be carried 
out by a contrast-enhanced MRI within 24–48 hours postoperatively, in order to distinguish 
between residual GBM, postoperative reactive changes and parenchymal damage as a result of 
surgery. Postoperative contrast-enhancing tumor mass is typically used to delineate residual 
GBM and completeness of removal. It is better to use volumetric analysis of the preopera-
tive and postoperative tumor to accurately measure EOR and residual volume (RV). Reactive 
postoperative changes can be seen as early as 18 hours on MRI, but usually does not appear in 
the first 3–4 days. The EOR was identified as a strong prognostic factor for survival in GBM, 
together with patient’s age and patient’s functional status. Surgical removal has a critical 
role in GBM management because the only potentially modifiable risk factor associated with 
survival is EOR. The gross-total resection is not always possible. Thus, several studies have 
been conducted to evaluate EOR threshold which may serve as minimum surgical goal to 
achieve. Other studies demonstrated that EOR is not an ideal indicator to the success of the 
surgery, because it is a percentage value, reported to initial volume of the tumor, which can 
vary widely. Contrast-enhancing RV is considered a more clinically relevant measure and a 
stronger predictor of survival than EOR, representing the tumor mass existing prior to start-
ing medical therapy. Chaichana et al. in 2014 evaluated newly diagnosed GBM patients who 
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underwent surgery and found that the minimum EOR of 70% and the maximal RV of 5 cm3 
showed statistical significance for prolonged survival and delayed recurrence [13]. Grabowsky 
et al. in 2014 reported that RV of 2 cm3 or less confers survival benefit to the patient [14]. There 
are models that argue for a continuous relationship between EOR and median survival, sug-
gesting that there is a survival advantage associated with any degree of resection [15]. This is 
evident for the practice of maximal safe resection for GBM.
Surgery is associated with some risk. Complications encountered in open surgery for GBM 
are those of craniotomy in general. There are reported morbidity rates ranging from 5 to 15% 
and mortality rates from 1 to 5% [8].
4.3. Intraoperative neurosurgical guidance
The key issue for glioma surgery is to accurately delineate the tumor into the operative 
field, which can be a challenge for the neurosurgeon. Many useful tools have been created 
to help the surgeon differentiate between tumor and normal tissue. It is important to adapt 
modern technologies to successfully guide maximal surgical resection without postopera-
tive neurological deficit. Multiple studies suggest that extensive resection is beneficial for 
the patient. But an excessive excision should be avoided, since it can induce permanent 
neurological dysfunction. At the same time, an incomplete resection can be therapeutically 
ineffective. The ideal goal of neurosurgery is to maximize the resection of the tumor mass 
safely, without impairing eloquent functions and quality of life. For higher efficacy and 
lower risk, the current concept of neurosurgery is an “information-guided surgery”, using 
multimodal intraoperative information to identify the positions of the eloquent brain areas 
accurately and in real-time [16, 17]. Anatomical information from navigation, ultrasonog-
raphy and intraoperative MRI, functional information from mapping and monitoring and 
histopathological data must all be considered to prevent unexpected deficits and promote 
extensive resection.
4.3.1. Image-based navigation
MRI neuronavigation (frameless stereotactic navigation) is based on preoperative 
MR-imaging data, taken with fiducial markers that are left in place on the scalp. This data 
is projected into the operative field for better anatomical orientation. It is useful for surgical 
planning and image guidance, particularly when the tumor cannot be seen on the cortical 
surface of the brain. However, it is rendered unreliable when variations in brain volume or 
shifts of the intracranial content appear during the surgery, because this technology is based 
on a preoperative set of images, without updating during surgery.
Intraoperative ultrasonography is helpful when the tumor is not isoechoic with the brain or 
the density difference is greater (when there is a hematoma or a cystic component into the 
mass lesion). It is a dynamic imaging modality that can guide the neurosurgeon in real-time 
during resection. It has the advantage that brain shift and brain relaxation that occur during 
the excision of the lesion do not influence the accuracy of the procedure. Three-dimensional 
sonography with navigation software solves any orientation problems.
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Intraoperative MRI systems are available, but the equipment is expensive and therefore the 
access is somewhat restricted for many neurosurgeons and patients alike. It has the advantage 
to avoid potential errors caused by brain shift. It provides information about the completeness 
of tumor resection during surgery and allows the surgeon to perform an additional tumor 
excision, if needed. However, it has a limited ability to delineate between residual glioma and 
adjacent normal brain. The system has been shown to improve the extent of tumor removal.
4.3.2. Intraoperative functional mapping and monitoring
Intraoperative functional mapping and monitoring are essential for safe excision of GBM local-
ized near eloquent cortex. It can accurately identify individual eloquent brain areas, including 
somatosensory cortex, motor cortex and language cortex, enabling the neurosurgeon to avoid 
these regions during tumor resection and thereby minimizing the risk of neurological morbid-
ity. One of the most important advantages of this method over the imaging techniques is allow-
ing assessment of the cortical and subcortical function in real-time. In addition, continuous 
monitoring of the patient’s neurological findings during surgery is very useful for intraopera-
tive feedback to the surgeon. Using these functional methods, the edge of resection can exceed 
the anatomical borders of the tumor (contrast-enhancing regions) to reach the functional border 
of the tumor (placed in the peritumoral tissues, invaded by the tumoral cells) [18].
Localization of the primary somatosensory cortex can be achieved by somatosensory 
evoked potentials (SSEPs) mapping, performed under general anesthesia or in awake patient. 
Techniques are similar to those used for routine diagnostic studies. Evoked potentials are 
recorded by stimulating peripheral afferent nerves (median nerve, posterior tibial nerve, etc.), 
usually electrically. Recording electrodes are placed on the cortical surface (typically proxi-
mal to the lesion). When recording SSEPs, the primary sensory cortex and primary motor cor-
tex generate potentials that are mirror images of each other. This “phase reversal” across the 
central sulcus aids in the localization of the primary motor cortex. Localization of the primary 
somatosensory cortex can also be performed by direct cortical electrical stimulation of the 
postcentral region. The awake patient communicates the presence or absence of the sensory 
symptoms triggered by stimulation.
Localization of the primary motor cortex can be accomplished using the SSEPs “phase rever-
sal” technique or by direct cortical electrical stimulation (with patient under general anesthe-
sia). It is recommended to use both techniques, starting with central sulcus identification and 
continuing with cortical stimulation of precentral regions and recording the muscle motor 
evoked potentials (mMEPs) from the corresponding muscles or observing clinical move-
ments [19]. The former technique is preferred, because the stimulation threshold for obtain-
ing mMEPs is smaller than that for obtaining clinical movements [8, 17, 19]. Thus, the risk 
of eliciting local or generalized seizure activity is decreased. During the cortical stimulation, 
simultaneous electrocorticogram (EcoG) recording is required for the safety of the patient. It 
is used to identify spontaneous or stimulation-induced epileptic discharges (after discharges), 
marking a subclinical seizure activity. It is important to have an adequate serum anticon-
vulsant level pre-operatively and, if necessary, additional intravenous boluses of antiepilep-
tic drugs may be considered [8]. It is of paramount importance to distinguish primary from 
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 supplementary motor areas as it is known that damage of the motor strip will cause a per-
manent postoperative motor deficit, while damage of the supplementary and premotor areas 
will result in a temporary postoperative deficit. Once the motor strip was identified, direct 
cortical stimulation or subcortical stimulation can be used for continuous evaluation of the 
functional integrity of the motor pathways during glioma resection.
Localization of the language cortex is performed under awake craniotomy (AC), by corti-
cal and subcortical direct electrical stimulation (DES). A “positive mapping” strategy can be 
used: a large craniotomy exposes the brain a good distance from the tumor and makes it 
possible to identify “positive” language sites (areas where a cortical stimulation induces a 
language function) prior to excision. Lately, a “negative mapping” strategy emerged as pref-
erable. It supposes to identify “negative” language sites, meaning regions where a cortical 
stimulation blocks a language function. This technique allows a smaller, tailored craniotomy, 
with a minimal cortical exposure around the tumor (up to 2 cm of surrounding brain) and a 
less extensive mapping. It is a more time-efficient neurosurgical procedure [17, 20, 21].
It is important to emphasize that stimulation mapping is used to identify essential language cor-
tex, whose injury will lead to permanent deficit. But there are also multiple nonessential speech 
areas. The essential language cortex is obviously different from involved language cortex iden-
tified by functional imaging techniques, such as functional MRI (fMRI) and positron emission 
tomography (PET). Although these imaging techniques have advanced considerably, they have 
some limitations and cannot replace intraoperative mapping. Patients who speak multiple lan-
guages have separate language sites for each of their different languages [8]. Different language 
tasks performed by a patient may lead to delineate distinct language sites. There is significant 
individual variability in the location of the language areas, sometimes the Broca area or the 
Wernicke area having a location beyond the classic anatomical boundaries or more than two 
essential speech areas being identified. Quinones-Hinojosa et al. found a variability of more than 
4 cm in the location of speech arrest when using classical neuroanatomic landmarks [22, 23]. 
Furthermore, cerebral topography is distorted by the tumor mass effect and brain plasticity can 
induce a functional reassignment [17, 20, 23]. Thus, intraoperative identification of the language 
areas is essential for extensively and safely removing GBMs located near these eloquent regions 
in the dominant-hemisphere. It is best to continuously monitor the patient’s ability to speak, espe-
cially during the part of the excision which is close to the identified language sites (within 2 cm). 
If the distance between resection border and the nearest language area is more than 1 cm, signifi-
cantly fewer permanent language deficits occur [20, 24]. A subcortical stimulation can be used 
into the resection cavity to guide the removal technique (when stimulation block the language 
function, the location is very close to the subcortical language pathways – 5 mm or less) [17, 25].
A new intraoperative method to assess integrity of functional interconnections between lan-
guage areas during surgery was proposed by Yamao et al. [17, 26, 27]. The authors monitored 
the integrity of the dorsal language pathway (arcuate fasciculus) using cortico-cortical evoked 
potentials (CCEPs). The technique is based on the electrical stimulation of the anterior perisyl-
vian language area while recording the average response from posterior perisylvian language 
area. It is clinically useful for evaluating the integrity of the language network and have the 
advantages that is task-free, do not require the cooperation of the patient and therefore can be 
performed also under general anesthesia [27, 28].
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4.3.3. Enhanced visual tumor demarcation
The ideal technique for sharper intraoperative delineation between tumor and the surround-
ing cerebral tissue should provide real-time information during resection, without concern 
about changes into the operative field and still be affordable.
Intraoperative tumoral tissue fluorescence due to specific enhancing agents provides a real-
time GBM discrimination in situ. The differences are visualized using specially designed micro-
scopes, equipped with appropriate filters to detect fluorescent light emission. Fluorescence is 
the emission of light with a short wavelength by a substance that has absorbed light of a 
longer wavelength. Fluorochrome is a fluorescent dye, used to stain biological material before 
microscopic examination. In neurosurgery of the gliomas, a specific fluorochrome is associ-
ated with glioma tissue (selectively if possible) and then illuminated by light. Fluorescent 
dye will emit light, which will be perceived by the surgeon using special filters. There are 
four types of approaches to intraoperative fluorescence: (1) tissue fluorescence induced by 
specific metabolic activity; (2) tissue fluorescence-based on passive permeability; (3) tissue 
fluorescence due to targeted fluorescent probes accumulated into the tumor tissue; and (4) 
autofluorescence [29].
Tissue fluorescence induced by specific metabolic activity is the basis to use of 5-aminolevu-
linic acid (5-ALA) in fluorescence-guided surgery. 5-ALA is an endogenous amino acid, the 
first compound in the porphyrin synthesis pathway. It is finally converted to protoporphyrin 
IX (PPIX), which chelates with iron in presence of enzyme ferrochelatase to produce heme 
(component of hemoproteins). GBM cells lack or have reduced ferrochelatase activity and this 
results in accumulation of protoporphyrin IX into the tumor tissue after oral administration of 
5-ALA. Protoporphyrin IX is clearly visualized by its red fluorescence under blue-violet light 
conditions, enabling differentiation of viable tumor from normal adjacent brain. 5-ALA is the 
only agent that has been approved in fluorescence-guided neurosurgery in Europe, Canada 
and Japan, and is commonly used in surgery of GBMs. It induces GBM tissue fluorescence, 
having high sensitivity, specificity, and positive predictive values for identifying malignant 
glioma tumor tissue [30, 31]. In recurrent malignant gliomas, fluorescence is observed in ana-
plastic foci, in regions of gliosis or invaded by inflammatory cells, but not in normal brain. 
Prior alternative treatment such as radiotherapy or chemotherapy does not invalidate 5-ALA-
induced fluorescence [32]. Fluorescence can discriminate malignant glioma cells down to a 
tumor cell density of approximately 10% [29, 33]. It is now demonstrated that visible fluores-
cence clearly extends beyond the border of preoperative MRI contrast-enhancement, PPIX 
accumulation being more sensitive than gadolinium enhancement [33, 34]. Thus, an extensive 
glioma resection beyond radiologically evident tumor can be performed. 5-ALA-guided resec-
tion of GBM was found to be beneficial, enabling surgeons to achieve a double rate of com-
plete resections of malignant gliomas in comparison with conventional techniques [31, 35]. A 
randomized controlled multicenter phase III trial conducted by Stummer et al. involving 270 
patients in 17 centers has examined a group undergoing 5-ALA fluorescence-guided surgery 
and a group undergoing conventional white light-guided surgery. The authors reported that 
gross-total resection evaluated on postoperative imaging was 65% in cases undergoing fluo-
rescence guidance compared with 36% in the white light group (p < 0.001), and progression-
free survival was 41 versus 21.1% (p < 0.003) [35].
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Tissue fluorescence based on passive permeability uses fluorescein or indocyanine green, 
which has not been approved for intracranial use. Fluorescein is a typical marker of compro-
mised blood-brain barrier (BBB), rather than a selective tumor marker, therefore its presence 
is highly nonspecific. It displays a yellow-green fluorescence visualized by the naked eye. 
Given its limited specificity, there is a great risk to remove normal, functional brain tissue, 
and given its sensitivity concerns, there is a risk of leaving residual tumor [36]. Recently, 
a dual-labeling approach has been proposed, using both PPIX and fluorescein fluorescence 
simultaneously. The advantage is that PPIX provides a reliable tumor detection and fluores-
cein gives a better background visualization, as it would be expected to accelerate surgery, 
while maintaining safety and efficacy [37]. Indocyanine green enables evaluation of tumoral 
and peritumoral blood flow and vascularization. It has the advantage of emitting light in the 
near-infrared region of the spectrum, therefore the fluorochrome can be visualized deeper in 
the tumoral tissue. However, the visualization requires special technologies.
Tissue fluorescence due to targeted fluorescent probes accumulated into the malignant tumor 
tissue is an ongoing subject of research. There are some fluorescent agents targeted or being 
retained by brain tumor cells undergoing clinical testing. Their effective application in clini-
cal settings requires development of detection instrumentation and additional studies. Agents 
that show promise for intraoperative discrimination of GBM include Tumor Paint (chloro-
toxin linked to a fluorophore), Angiopep-2 targeting agents, epidermal growth factor receptor 
(EGFR)-targeted agents, PTPμ-targeted SBK agents, the fluorescently labeled poly (ADP-ribose) 
polymerase 1 (PARP-1) inhibitor (CLR1502) and αvβ3 integrin-targeted agents [38, 39].
Microspectrofluorometry can be used to measure the autofluorescence spectrum of biologi-
cal tissues both ex vivo on resected samples and in vivo, during surgery, by means of fiber 
optic probe. It is a dye-free method, based on the intrinsic autofluorescence properties of a 
tissue. In glioma, the autofluorescence profile is distinct from normal brain, due to changes of 
biochemical composition and histological organization. There are differences in both spectral 
shape and signal amplitude relative to normal cortex and white matter. These differences 
allow the use of autofluorescence in situ as a parameter for distinguishing neoplastic from 
normal condition and so to better delineate GBM resection margins [40–42].
Confocal microscopy (laser scanning confocal microscopy – LSCM) may provide in vivo 
images by optical sectioning, characterized by higher resolution and contrast, with magnifica-
tion up to 1000x. These images enable intraoperative visualization of tumor histopathological 
features and cell morphology in real-time, in three dimensions, without the need for extensive 
traditional tissue processing [36]. Intraoperative confocal imaging correlates with histopatho-
logical analysis, the diagnostic accuracy being of up to 93% [43]. The major application of 
confocal microscopy is for imaging tissues labeled with fluorescent probes. In GBM surgery, 
confocal microscopy combined with tissue fluorescence provides a reliable identification of 
tumor cells and tumor-brain interfaces.
4.3.4. Intraoperative sampling
The diagnostic of GBM is usually confirmed by standard postoperative histopathological 
examination of tissue sections with results only available several days after the surgery has 
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finished. But the maximal removal of the glioma is the key component in the specific treatment, 
a smaller volume of postoperative residual tumor being associated with an improved progno-
sis. One of the difficulties of achieving an optimal excision is failure to delineate the resection 
margins. Nevertheless, histopathological assessment is also available during the surgery, pro-
viding important diagnostic information. Even if such information is less reliable compared 
with that of postoperative approaches, sometimes intraoperative sampling is the sole source of 
diagnostic arguments for deciding the extent of resection. Precision increases with the number 
of tissue sections. Traditional histopathological techniques made intraoperative include frozen 
section and imprint cytology. They are time-consuming (requiring nearly 30 mins), laborious 
and subjective. It is desirable that they are performed by a skilled pathologist.
Mass spectrometry-based molecular analysis can rapidly provide detailed molecular informa-
tion about tumor and adjacent brain tissue, allowing an intraoperative diagnosis and guidance 
in detection of the boundaries between glioma and normal brain. The desorption electrospray 
ionization mass spectrometry (DESI-MS) is a mass spectrometric imaging technique for charac-
terizing lipid profile within tumor specimens. Because DESI-MS can be performed rapidly (min-
utes) and routinely, in the ambient conditions, with minimal pretreatment of biological samples, 
it can be used during surgery. It quickly provides a valuable diagnosis of tumor type based on 
lipid pattern [44]. It can also detect oncometabolites: 2-hydroxyglutarate and N-acetylaspartate. 
2-hydroxyglutarate is present in small amounts in normal brain tissue, but its concentrations 
are extremely high in gliomas with mutations in IDH1 and IDH2 [45–47]. It could be used as a 
biomarker and serve as an important prognostic indicator. Detection of 2-hydroxyglutarate in 
operative field with precise spatial distribution could also help define surgical margins. DESI-MS 
provide valuable information that is unattainable by traditional histopathological techniques.
4.4. Intratumoral therapies
Given that GBM is typically a solitary tumor, with local recurrence and very rare metastases, 
the disease is a proper candidate for local treatment. On the other hand, availability of drugs 
which can cross the BBB has severely limited the effective therapies against GBM. Strategies to 
bypass this barrier have been developed. Localized drug delivery into a postoperative tumor 
bed is an attractive option for administration of therapeutics while avoiding systemic side 
effects. Furthermore, this way provides a means for administration of new, tumor-selective 
molecules that are often largely excluded by brain.
Controlled-release polymer systems, like carmustine wafers (Gliadel wafers) can be implanted 
in the resection cavity. Another local approach is catheter-based convection-enhanced deliv-
ery (CED) of conventional or novel agents through continuous low-positive-pressure bulk 
flow. Intracavitary delivery of highly localized doses of irradiation is feasible through GliaSite 
system brachytherapy.
4.5. Recurrence
Standard therapy in newly diagnosed GBM involves maximal safe surgical resection fol-
lowed by radiotherapy (RT) with concurrent and adjuvant TMZ. Despite this first-line treat-
ment, recurrence inevitably occurs, most patients experiencing it after 7–8 months of primary 
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treatment. There are no well-defined management protocols for recurrent GBM. Options for 
second-line treatment are limited and include repeat surgery, re-irradiation, chemotherapy, 
novel therapies, supportive care or, better, a combination of these.
The standard neuroimaging modality for the follow-up of GBM is contrast-enhanced MRI, 
which is performed every 2–3 months while the patient is on therapy. Criteria to assess treat-
ment response and progression have been established by the Response Assessment in Neuro-
Oncology (RANO) Working Group [48]. Progression is defined as at least 25% increase in the 
contrast-enhancing MRI lesion (the product of the maximal cross-sectional enhancing diame-
ters of tumor area). Diagnosing a true progressive tumor growth after chemoradiation by MRI 
alone remains a challenge, because it is very difficult to distinguish between post-treatment 
radiation effects (such as pseudoprogression or radiation necrosis) and tumor recurrence. 
Post-treatment radiation effects can be divided into pseudoprogression and radiation necro-
sis. Pseudoprogression appears several weeks up to 3 months after RT (5.5–31%), whereas 
radiation necrosis occurs 3 months to years after irradiation (3–24%) [49]. Radiation necrosis 
is a space-occupying necrotic lesion, with mass effect and neurological dysfunction. It is irre-
versible and progressive. Its features on MRI are often identical to that of recurrent GBM. The 
differentiation is very important, because the management is different. Advanced MRI 
techniques such as DWI, DTI and PWI provide additional information. Metabolic imaging 
techniques like PET, single-photon emission computed tomography (SPECT) and MR spec-
troscopy (MRS) are helpful in differentiating between tumor recurrence and therapy-related 
changes. Tumor recurrence appears as a lesion metabolically active, while radiation necrosis 
appears metabolically inactive. However, no imaging modality has sufficient specificity and 
tissue biopsy remains the gold standard to obtain a definitive diagnosis.
GBMs typically recur focally and in many cases surgery is possible. Repeat surgery is per-
formed in approximately 25% of cases. Although a repeat surgery is associated with a higher 
complication rates than the initial surgery, this increase is rather small and clearly acceptable 
[50, 51]. However, its efficacy is debated. Many recent studies reported a survival benefit 
and an improvement of quality of life resulting from repeat resections in selected patients. 
Performing an overview of the current literature on second surgery for recurrent GBM, 
Montemurro et al. found the median overall survival from diagnosis being 18.5 months and 
the median survival from second surgery being 9.7 months [51]. Extent of resection at reop-
eration has been demonstrated to improve overall survival, thus a maximum safe excision 
should be the surgical goal. The decision of a second surgery should be individualized and 
should involve a multidisciplinary team approach. The age and the preoperative performance 
status are the most important predictors of a prolonged survival. A more favorable prognosis 
following surgery for recurrence is associated with a younger age (< 60 years) and a good pre-
operative performance status (KPS ≥ 70) [51]. Reoperation is not recommended for patients 
with involvement of eloquent brain regions.
Thus, patients with recurrent GBM may benefit from resection of tumor whenever safely 
possible. Repeat surgery can help in providing symptom relief and differentiating tumor 
recurrence from pseudoprogression, radiation necrosis, respectively. But surgery should be 
followed by adjuvant therapies.
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5. Radiation therapy
The SoC for newly diagnosed GBM consists of maximal safe surgical resection followed by 
radiotherapy (RT) plus concomitant and adjuvant TMZ.
Following gross-tumor removal, the final histological diagnosis is established, and RT should 
start. The optimal time to initiate radiation is controversial. There are studies showing worse 
outcomes and even decreased survival when radiation is delayed [52, 53]. Irwin et al. found 
that a 6 weeks delay (from 2 weeks postoperative to 8 weeks) reduces median survival by 
11 weeks for a “typical” patient [52]. But there also studies showing no association between 
timing of radiation initiation and outcomes [54, 55] and studies suggesting a possible ben-
efit of delay (however, up to a reference range of time) [56, 57]. Blumenthal et al. analyzed 
the relationship between the delay of RT and the outcome on a large cohort of more than 
2800 patients. They observed no obvious reduction in survival with increasing delay (within 
relatively narrow temporal limits—6 weeks). Indeed, median survival time was unexpect-
edly greater in the group with the longest interval (>4 weeks) than in those with the shortest 
delay (≤2 weeks), respectively, 12.5 months versus 9.2 months (P < 0.0001). The authors do not 
exclude the possibility that an adjuvant treatment initiated beyond 6 weeks postoperatively 
may be detrimental [56]. In other studies, Han et al. found a narrow range of time (from 30 
to 34 days after surgery) where there is prolonged overall survival and prolonged progres-
sion-free survival compared with early initiation of concurrent chemoradiation [57, 58]. In 
common practice, the patient commonly waits about 4 weeks before adjuvant therapies. It is 
generally agreed that a postoperative delay of 6 weeks may not be critical.
Concomitant TMZ and RT (known as the Stupp regimen) have been shown to be more 
effective than radiation alone with minimal additional toxicity. After the end of radiation, 
an adjuvant treatment with TMZ is indicated. Patients who received RT and concurrent 
TMZ presented a median survival of 14.6 months versus 12.1 months with RT alone [59]. 
Furthermore, the two-year survival rate was 26.5% with RT plus TMZ versus 10.4% with RT 
alone. This is the current SoC for patients with newly diagnosed GBM up to age 70, with a 
good performance status (Karnofsky Performance Status (KPS) ≥ 60).
RT using three-dimensional conformal beam or intensity-modulated RT is used now. The typ-
ical total dose delivered is 60 Gy in 2 Gy fractions, administered 5 days per week for 6 weeks 
and there is no evidence that higher doses improve outcome [60, 61]. The RT involved fields 
should include the tumor bed with a 2–3 cm margin, based on the observation that GBM com-
monly recurs within 2 cm of the original tumor location in 80–90% of cases.
The optimal management of elderly patients is controversial. In practice, for patients 
>70 years old or for patients <70 years old with a poor performance status (KPS < 60), an alter-
native hypofractionated regimen can be considered. For elderly not suitable for radiation, 
chemotherapy alone may be an option.
Despite maximal multimodal treatment, GBM invariably recur, disease progression occurring 
within the first year in about 70% of cases. In selected cases of recurrences, a second course of 
radiation may be possible, but tolerance of local brain tissue to radiation is limited and there 
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is an increased risk of radiation necrosis. This may lead to neurological dysfunction, edema 
and mass effect. Radiation necrosis is very difficult to distinguish from progressive disease 
solely by imaging techniques. Histology remains the gold standard for diagnosis. Combs 
et al. investigated the role of re-irradiation using the fractionated stereotactic approach and 
demonstrated a median survival of 8 months and a progression-free survival of 5 months for 
patients with GBM [62].
Stereotactic radiosurgery offers the potential of providing a “boost” radiation to a portion 
of the radiation field in newly diagnosed patients or treating a small recurrence, being an 
alternative to open surgery [63]. However, its applicability remains very limited in absence of 
studies which could demonstrate a statistically significant benefit.
Intracavitary brachytherapy using the GliaSite system can be used in selected newly diag-
nosed patients or in recurrent disease, intending to deliver an additional radiation to the sur-
gical cavity wall. It is a medical device, composed of a balloon that will contain a radioactive 
solution with 125I during the period of irradiation, connected through a catheter to an infusion 
port. The balloon is placed in the resection cavity during surgery and the radioactive solution 
is injected later. Re-irradiation of recurrent GBM with GliaSite Radiation Therapy System 
after resection seems to provide a median survival of approximately 9 months [64, 65].
6. Chemotherapy
For the time being, TMZ is considered the first-line chemotherapy drug in GBM. It is an oral 
systemic drug with a good penetration of the BBB and limited side effects. The mechanism of 
action is based on its ability to alkylate/methylate DNA. This alkylation damages the DNA 
and triggers the death of tumor cells. MGMT (O6-methylguanine-DNA methyltransferase) is 
a DNA-repair enzyme that rescues glioma cells from damages induced by alkylating agents 
like TMZ or carmustine. High activity of MGMT in tumor cells creates resistance to chemo-
therapy with alkylating agents and may determine treatment failure. Epigenetic silencing of 
the MGMT gene by promoter methylation is associated with decrease of DNA-repair activity 
and thus tumor cells will be more responsive to TMZ. In other words, the methylation status 
of MGMT promoter is associated with a benefit from alkylating agent-based chemotherapy 
in GBM. Numerous studies have confirmed that carriers of the methylated form of MGMT 
promoter with GBM treated with TMZ and RT have a prolonged overall survival [66–68]. 
Hegi et al. found that their median survival was 21.7 months as compared with 15.3 months 
among those who were assigned to only RT [69]. Furthermore, assessing MGMT methyla-
tion status in a cohort of patients with GBM who underwent radiation treatment but did not 
receive chemotherapy, Rivera et al. have demonstrated an 50% reduction in the rate of tumor 
progression during RT in methylated tumors versus those that were unmethylated. These 
data suggest that MGMT promoter methylation may predict a better response to any form 
of therapy, including RT [70]. Consequently, MGMT promoter methylation status has been 
established as an important prognostic biomarker, helping in performing a risk stratification 
of cases. National Comprehensive Cancer Network (NCCN) guidelines consider MGMT pro-
moter methylation status in clinical management of the patients with GBM.
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For newly diagnosed GBM, TMZ is typically given following surgical resection, concurrent 
and adjuvant, in addition to RT. It is administered daily at a dose of 75 mg/m2 for 6 weeks 
during irradiation, followed by a rest period of about 1 month after RT is completed (concur-
rent treatment). When restarted, TMZ is dosed at 150 mg/m2 daily for 5 days every 4 weeks 
for 6 cycles (adjuvant treatment). If tolerated, the dose of the adjuvant treatment can be esca-
lated up to 200 mg/m2 daily. This is the well-known Stupp regimen. In common practice, 
some medical centers have attempted to prolong TMZ administration for 12–18 months. Some 
evidence suggests that long-term therapy with TMZ in selected patients is superior to Stupp 
regimen [71–73], but there is no definitive data to prove this.
The use of standard or hypofractionated RT plus concomitant and/or adjuvant TMZ has been 
extended to elderly (> 70 years old) with a good performance status (KPS ≥ 60). For patients 
>70 years old with a poor performance status (KPS < 60), TMZ alone can be an option.
At the time of recurrence, reoperation should be proposed if the tumor is resectable and if 
prognostic factors suggest a benefit. Local chemotherapy can be administered during surgery 
by implantation of Gliadel wafers. Second-line chemotherapy is indicated based on MGMT 
promoter methylation, time to disease recurrence and toxicity profile. The nitrosourea-based 
regimen is the preferred choice. Restarting therapy with TMZ may be an option in MGMT-
methylated patients. Other agents, such as carboplatin, etoposide, irinotecan may be tried as 
single agents or in regimens.
Gliadel wafers are composed of a biodegradable polymer impregnated with carmustine 
(BCNU), an alkylating agent of the nitrosourea family. During the surgery, after removal of 
the tumor, up to 8 wafers (containing a maximum of 61.6 mg BCNU) are deposited along the 
wall of the resection cavity and left in situ. BCNU will be release over a period of 2–3 weeks, 
the tumor cells being directly and efficiently exposed to high levels of drug starting immedi-
ately after surgery. Gliadel has received FDA (USA) approval for use in both newly diagnosed 
GBM and recurrences. Studies have consistently reported an increase of median survival by 
about 2 months [74–76]. Local delivery of carmustine reduces systemic adverse events, but 
sometimes induces complications: cerebral edema, seizure, poor wound healing, cerebrospi-
nal fluid (CSF) leak, infection, headache, hemiparesis, hydrocephalus, particularly in patients 
with recurrent GBM. Combining local and systemic chemotherapy offers advantages that may 
explain the prolonged survival. First, systemic TMZ is most effective in regions of the tumor 
that are most vascular, whereas local release of BCNU allows direct access to relatively avascu-
lar areas of walls of the surgical cavity. Second, following the Stupp protocol, between surgery 
and chemoradiotherapy there is a period without treatment. Gliadel allows treatment of resid-
ual tumor cells within this period. Therefore, the combination of different treatment modalities 
allows continuous therapy up to 9 months, beginning immediately following surgery [77].
7. Other therapies
Optune (formerly NovoTTF-100A) is a device that delivers tumor-treating fields (TTFields), 
meaning low-intensity, intermediate-frequency, alternating electric fields that have 
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antiproliferative properties with minimal toxicity. It has been approved (FDA 2015) as an 
alternative treatment for adult patients having a newly diagnosed supratentorial GBM fol-
lowing debulking surgery and completion of RT, with concomitant SoC chemotherapy. It has 
also been approved (FDA, 2011) for the treatment of adult patients with supratentorial con-
firmed recurrences of GBM, to be used as a monotherapy, as an alternative to standard medical 
therapy after surgical and radiation options have been exhausted (Novocure, 2017). Current 
evidence supports the use of TTFs as a therapeutic option. Stupp et al. analyzed 315 patients 
with GBM who had completed standard chemoradiation therapy, adding TTFields to mainte-
nance TMZ chemotherapy and found a significantly prolonged progression-free survival and 
overall survival. Median progression-free survival was 7.1 months in the TTFields plus TMZ 
group and 4 months in the TMZ alone group. Median overall survival was 20.5 months in the 
TTFields plus TMZ group and 15.6 months in the TMZ-alone group [78].
8. Emergent treatments strategies
As the field of neuro-oncology continues to progress, numerous novel therapies have been 
tried and tested. Results from preclinical and clinical studies applying new treatments alone 
or in combination with conventional methods are promising.
GBM has abnormalities in cellular signal transduction pathways. All these pathways include 
receptor tyrosine kinases (RTKs) like vascular endothelial growth factor (VEGF), epidermal 
growth factor (EGF), platelet-derived growth factor (PDGF), etc., and share common mech-
anisms of activation and intracellular signaling, meaning RAS or phosphoinositol-3-kinase 
(PI3K) pathways. Genetic alterations of RTK/RAS/PI3K occur in about 88% of primary GBMs; 
the pathways are overactivated, allowing uncontrolled cellular proliferation, survival and 
invasion [79, 80]. Targeted molecular drugs have been developed to inhibit aberrantly acti-
vated signaling pathways in the clinical setting.
Increased epidermal growth factor receptor (EGFR) signaling has been reported in approxi-
mately 45% of GBM [79, 80]. It results in tumor cell proliferation, invasiveness, migration, 
angiogenesis and inhibition of apoptosis. Moreover, in the clinical setting, EGFR overexpres-
sion is associated with resistance to RT while EGFR inhibitions increased sensibility to RT 
[81]. Inhibitors of EGFR have been developed to block-specific pathways, but the results are 
disappointing. These include: monoclonal antibodies (cetuximab and nimotuzumab), small 
molecule tyrosine kinases inhibitors TKIs (gefitinib and erlotinib), a dual EGFR and ErbB-2 
inhibitor (lapatinib), a pan-ErbB inhibitor (canertinib), a dual EGFR and vascular endothelial 
growth factor receptor (VEGFR) inhibitor (vandetanib), irreversible EGFR inhibitors (BIBW 
2992 and PF-00299804), etc. It is to be noted that the ErbB family of proteins contains four 
receptor tyrosine kinases, structurally related to EGFR, marked as ErbB-1 to ErbB-4. ErbB-1 
and ErbB-2 are found in many human cancers.
Overexpression of alpha subtype of PDGF receptor (PDGFR) occurs in about 13% of GBM 
[79]. Imatinib mesylate and tandutinib are inhibitors of PDGFR and other molecules involved 
in intracellular signaling pathways.
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VEGF is a key factor implicated in tumor neoangiogenesis. GBM is a highly vascular tumor, 
that depends on vascular proliferation for growth. Recent evidence suggests vasculogenic 
mimicry in GBM, meaning formation of vessel-like network by tumor cells, allowing a blood 
supply for tumor growth. This process differs from angiogenesis, it is happening without the 
presence of endothelial cells. Angiogenesis is driven primarily by tumor-secreting VEGF-A 
(one member of the VEGF family), but there are many secreted proangiogenic factors [82]. 
The level of VEGF in HGG is greater than 10-fold compared with LGG [83]. Thus, drugs have 
been developed to interfere with angiogenesis by directly blocking ligand (VEGF) or receptor 
(VEGFR) or by targeting proangiogenic molecules that function by alternative mechanisms 
[84]. Of all targeted biological agents, only bevacizumab (Avastin) has demonstrated efficacy. 
It is a humanized monoclonal antibody that selectively blocks VEGF and so the BBB becomes 
more stable, with a resultant decrease in vascular permeability and edema, such that the 
corticosteroid doses can be reduced or suspended. Bevacizumab may be useful during and 
after RT, because of reduction of peritumoral edema, sometimes refractory to corticosteroid 
drugs and because of reduction of radiation necrosis rate following improving oxygenation. 
It has been approved by FDA (2009) as a single agent in the treatment of recurrent GBM fol-
lowing prior therapy, based on improvement in progression-free survival (that however did 
not translate into an improvement in overall survival) and a modest toxicity profile. Patients 
treated with bevacizumab inevitably relapse and sometimes an aggressive, invasive “glioma-
tosis” pattern of recurrence, unresponsive to subsequent therapy is observed. In addition to 
bevacizumab, there are many inhibitors of VEGF/VEGFR and other relevant targets under 
investigation, including: vatalanib, cediranib, sunitinib, sorafenib, vandetanib, VEGF trap, 
ramucirumab, pazopanib, etc. Dually targeted VEGFR/PDGFR inhibitors may prove useful, 
because of role of PDGFR in pericyte recruitment.
Other antiangiogenic approach targets the integrins αvβ3 and αvβ5 that are overexpressed 
by tumor endothelial cells. They are transmembrane receptors that interact with extracellular 
matrix proteins to facilitate angiogenesis and invasion. Cilengitide inhibits these integrins.
There are clinical studies focused on substances that inhibit intracellular signaling mole-
cules. Overactivation of the PI3K/Akt/mTOR signaling in GBM has been observed, because of 
receptor tyrosine kinase overactivity, mutated oncogenic PI3K subunits, and/or loss of PTEN 
tumor suppressor activity. Several mTOR inhibitors are currently tested, including sirolimus, 
temsirolimus, everolimus, and ridaforolimus. Enzastaurin is an inhibitor of protein kinase 
C-β2 that suppresses PI3K/Akt pathway. Overactivation of RAS/RAF/mitogen-activated pro-
tein kinase pathway in malignant glioma has provided the rationale to study farnesyl trans-
ferase inhibitors (farnesylation is a critical step in activation of RAS). Tipifarnib, lonafarnib 
and sorafenib may inhibit farnesyltransferase. Histone deacetylase inhibitors (vorinostat, 
romidepsin, valproic acid, etc.) prevent gene transcription, resulting in cell cycle arrest, dif-
ferentiation, and/or apoptosis of tumor cells. Clinical trials are in progress.
Immunotherapy has become a promising cancer treatment, which allows for synergistic mul-
timodal strategies. There are different immunotherapeutic approaches in GBM, including 
active immunotherapy (tumor vaccination therapy) and passive immunotherapy (antibody-
based immunotherapy, adoptive cell therapy and other immune-modulatory therapy). Tumor 
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 vaccination therapy uses administration of the antigens to activate an antitumor immune 
response. There is a vaccine targeting the mutant of epidermal growth factor receptor EGFRvIII 
(only expressed in GBM cells in about 20–25% of cases) – rindopepimut. Vaccination with den-
dritic cells is based on their ability to absorb all kinds of antigens and to secrete interleukin-2, 
thus activating T lymphocytes and initiating an efficient and specific immune response [85]. 
The application of tumor-derived heat shock proteins as tumor antigen carrier may be effective 
in boosting immune response. Antibody-based immunotherapy refers to the use of specific 
interaction between antibodies and antigens to block negative immune regulatory molecules 
that would have been preventing activated T cells from attacking the cancer cells. The most 
promising class of drugs that emerged is based on immune checkpoint inhibitors. Nivolumab 
and pembrolizumab are antibodies targeting the receptor programmed cell death-1 (PD-1) 
receptor of lymphocytes. Ipilimumab is an antibody that binds cytotoxic T lymphocyte-asso-
ciated antigen 4 (CTLA-4), which would have inhibiting cytotoxic T lymphocyte to destroy 
cancer cells. Adoptive cell therapy is based on infusion of activated immune effector cells into 
cancer patients with the goal to enhance antitumor immunity. Immune effector cells include 
lymphokine-activated killer (LAK) cells, natural killer (NK) cells, T cells, tumor-infiltrating 
lymphocytes (TILs), cytotoxic T lymphocyte (CTLs), tumor antigen-specific TCR-transgenic T 
cells and chimeric antigen receptors-modified T cells (CAR T) [86]. This approach would be 
beneficial to non-responsive patients and non-immunogenic tumors.
Gene therapy is designed for delivery of genetic material, usually transgenes or viruses, 
into cells for therapeutic purposes. There are four types of gene therapy proposed for the 
treatment of GBM: suicide gene therapy, immunomodulatory gene therapy, tumor-suppres-
sor gene therapy, and oncolytic virotherapy. Suicide gene therapy uses genes that encode 
enzymes able to convert a non-toxic drug into an active cytotoxic compound. The herpes 
simplex virus (HSV) type 1 thymidine kinase (tk) gene has been used as a “suicide gene”, 
allowing to tumor cells to produce high levels of tk. Ganciclovir is the systemically injected 
prodrug, that will be converted by tk into a toxic metabolite. This compound is incorporated 
into DNA of actively proliferating tumor cells, and consequently blocks DNA replication and 
inhibits cell division. Apoptosis underlies the mechanism of cytotoxicity [87]. Another “sui-
cide gene” is cytosine deaminase (CD), an enzyme capable to convert an antifungal drug, 
5-fluorocytosine (5-FC), into the highly toxic compound 5-fluorouracil (5-FU). This is again 
converted into molecules which interfere with RNA processing and DNA synthesis and apop-
tosis invariably occurs. Immunomodulatory gene therapy induces or augments an enhanced 
specific antitumoral immune response, overcoming the tumor-induced immunosuppression. 
Tumor-suppressor gene therapy aims to restore the function of a tumor-suppressor gene lost 
or functionally inactivated in cancer cells. They play a critical role in maintaining genome 
integrity and in regulating cell proliferation, differentiation, and apoptosis. In GBM, there 
is at least one tumor-suppressor gene mutated or deleted in all cases; in 91% of patients, 2 
or more of these tumor-suppressor genes are inactivated [88]. Correcting the genetic abnor-
malities in the glioma cells has been demonstrated to suppress tumor growth via induction of 
apoptosis and cell cycle arrest. Genes encoding p53, p16, or phosphatase and tensin homolog 
(PTEN) can be candidates for this type of therapy. Oncolytic virotherapy employs replica-
tion-competent viruses with natural or engineered tropism and activity against tumors. They 
specifically infect and replicate in target tumor cells. During progeny particle release, tumor 
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host cells are destroyed, and tumor-associated antigens are released, while progeny virions 
infect neighboring tumor cells. Finally, a complete destruction of the tumor can be achieved, 
multiple mechanisms being involved together with direct oncolysis, meaning induction of an 
effective antitumor immune response, cancer cell starvation by destruction of tumor vascu-
lature, and sometimes the activity of virally encoded therapeutic transgenes. The two most 
studied oncolytic virus types are adenoviruses and herpes simplex viruses. Another strategy 
of gene therapy targets genes that may modulate the tumor microenvironment, to create 
unfavorable conditions for tumor growth or enhance the efficacy of therapy. Although there 
is a limited evidence of a therapeutic benefit of gene therapy to date, it is important to note 
that these therapies appear to be safe.
9. Conclusions
Effective treatment in GBM remains one of the most formidable challenge in neuro-oncology. 
Treatment is multimodal and despite significant advances in diagnostic technology, surgical 
technique, radiation, chemotherapy and targeted therapy, the prognosis remains poor. Large-
scale research efforts are required to understand the molecular biology of brain tumors and 
to discover novel therapies. Synergistic multimodal strategies and individualized treatments 
are likely to be the best approach of these complex tumors to finally improve survival and 
quality of life of the patients.
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